Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 14, Issue 1, 2012, Pages 40-46

  Henry, R R ^a   Aroda, V R ^b   Mudaliar, S ^a   Garvey, W T ^c   Chou, H S ^d   Jones, M R ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d DAIICHI SANKYO INC   (United States)

Author keywords

Bile acid sequestrant; Colesevelam; Glucose; Insulin sensitivity; Type 2 diabetes mellitus

Indexed keywords

COLESEVELAM; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; EXERCISE; FEMALE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 83655161342     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01486.x     Document Type: Article

References (13)

1. Daiichi Sankyo Inc. Welchol (colesevelam hydrochloride) US prescribing information. Parsippany, NJ: Daiichi Sankyo Inc., 2010.
2. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008; 168: 1975-1983.
3. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31: 1479-1484.
4. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008; 168: 1531-1540.
5. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
6. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 1987; 36: 914-924.
7. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
8. Schwartz SL, Lai YL, Xu J, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord 2010; 8: 179-188.
9. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 386-390.
10. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007; 74: 338-343.
11. Nakatani H, Kasama K, Oshiro T, Watanabe M, Hirose H, Itoh H. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism 2009; 58: 1400-1407.
12. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8: 369-385.
13. Hofmann AF. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 2009; 49: 1403-1418.